TL;DR (60 seconds)
TransMedics (NASDAQ: TMDX) makes the only FDA-approved warm-perfusion organ care system — the upgrade from a glorified ice cooler to a portable physiology lab. The same company is a defendant in an active securities-fraud class action filed after a 342-page short-seller report assigned it a $0 price target. Both things are true. The market knows both — and that is why the multiple compressed from peak ~$170s to $113.21 while revenue grew +37% to $605.5M in 2025 and management guided +20–25% for FY26.
The variant view: US heart penetration is just ~25% in the 2026 guide year (1,124 OCS Heart units against 4,572 US heart transplants in 2024 per OPTN). Multi-organ kidney expansion (~28,000 US kidney transplants/year) launches this year. The National OCS Program — 22 fixed-wing aircraft, 16 launch points, dedicated procurement surgeons — is the moat, not the device.
The trade — 250 days, target ~Jan 2, 2027:
Scenario | Probability | Target | Δ from $113.21 | Drivers |
|---|---|---|---|---|
Bear | 30% | $90.57 | −20% | Q1 disappoints + adverse Jewik ruling, DOJ subpoena, or settlement charge |
Base | 45% | $135.85 | +20% | Q1 in line, FY26 guide reaffirmed, lawsuit drags without adverse ruling |
Bull | 25% | $169.82 | +50% | Q1 beat + FY26 guide raised + Jewik dismissed or settled cheap |
Probability-weighted EV +16%. Reward/risk 1.6:1 base, 4.0:1 bull. Confidence 76/100. Position 1.5% of model book. Hedge required.
The May 5 Q1 earnings is the binary trigger. Before then, the multiple is depressed because the binary is unresolved. After then, if the thesis is right, the entry price is gone.
1. The setup — why TMDX is interesting now
Five years ago, every donor heart, lung, or liver in America rode in a cooler full of ice. Surgeons had ~4 hours of cold ischemic time before graft dysfunction risk spiked. Long-distance procurement was rare. Donation-after-circulatory-death (DCD) hearts were largely unusable because the warm ischemic interval between circulatory cessation and cold preservation degraded the organ.
TransMedics built the upgrade. The Organ Care System (OCS) is a portable normothermic perfusion device. The donor heart, lung, or liver beats, breathes, or metabolizes inside the box at body temperature — with arterial oxygenation and metabolic substrate delivery — while it travels.
The clinical case is honest, not heroic. The PROCEED-II trial showed survival outcomes non-inferior to cold storage; a Danish study reported 6-month event-free survival of 77.8% (OCS) versus 79.5% (cold) — not statistically distinguishable. The economic case is not "OCS produces better outcomes than ice." It is: OCS extends viable preservation time from ~4 hours to 8+ hours, which (a) expands the geography of what is reachable for procurement and (b) unlocks DCD donors. Both add to the transplantable supply.
US heart transplants in 2024: 4,572 (OPTN). TMDX 2026 OCS Heart guide: 1,124 US units. Implied penetration: ~24.6%. The runway is years, not quarters.
2. The variant view — what consensus is missing
Consensus tape on TMDX after the Scorpion-driven multiple compression:
"Hyper-growth medtech that already had its run. Deceleration is structural. Competitive entry from Paragonix (Getinge-owned) and XVIVO threatens the moat. Class action is an unquantifiable overhang."
What the data says:
Penetration is wide open, not maturing. Heart penetration in the 2026 guide is ~25%. Even under a conservative 50% saturation cap (the natural ceiling if cold storage remains the default for DBD short-haul cases), heart-only runway is another ~25 percentage points — doubling current case volume. Multi-organ commercialization adds the asymmetry: kidney clinical launch in 2026 against ~28,000 US kidney transplants per year is the largest single TAM lever in medtech transplant infrastructure.
NOP is the moat, not the device. The National OCS Program is not a sales channel — it is a logistics network. Twenty-two fixed-wing aircraft. Sixteen launch points across the continental US. Cardiothoracic procurement surgeons employed by TransMedics. OCS perfusion specialists deployed on-site. A competitor can sell a device. A competitor cannot replicate this stack in 18 months.
The competitive set is mis-categorized. Paragonix (acquired by Getinge for $477M in 2024) is static cold storage — a structured cold-pack improvement on ice that does not compete with normothermic warm perfusion for the long-haul or DCD use cases that drive OCS economics. XVIVO Perfusion is profitable, lung-focused, and European-anchored, with limited US heart presence. TMDX entering dynamic cold perfusion in H2 2025 marks the first direct competitive overlap — on TMDX's terms, with the broader logistics network behind it.
The multiple compression is partly fundamental, partly overhang. EV/NTM revenue compressed from peak ~10x to ~5.2x today, against a high-growth medtech peer median of ~8–10x. Three turns of EV/Sales = $90–150 of fair-value upside on a partial peer re-rate. Sell-side median 12-month price target is $146.50 (per MarketBeat, 9 Buy / 3 Hold / 0 Sell), implying ~6.5x EV/NTM revenue — partial re-rate, not full.
3. The catalyst calendar
Date | Event | Why it matters |
|---|---|---|
2026-05-05 (after market close) | Q1 2026 earnings + 4:30 PM ET call | The hard print. Watch: NOP case count YoY, OCS Heart unit growth, FY26 guide reaffirmation/raise, DCD heart commentary. |
2026-Q3 (est.) | OCS ENHANCE Heart trial readout | FDA-approved expansion trial; broader label and reimbursement |
2026-Q3 | OCS Kidney program clinical launch | Largest TAM expansion lever |
2026-H2 | Possible NOP IDN partnership announcement | Logistics moat hardening |
The 8-day window from publication to the May 5 print is the trade window. This is intentional. The multiple is depressed because the binary is unresolved.
4. The risks — what kills this trade
🚩 Jewik / Scorpion legal overhang. Discovery-stage adverse finding, DOJ or OIG subpoena, or material settlement charge could re-trigger a plunge to ~$70 (−40%). General base rate for securities class actions: ~90% are dismissed or settled (typically 1–4% of market cap), but the timeline to clarity is 18–36 months. We are inside that window today. Mitigation: 1.5% sizing + post-print put protection. Risk capped, not eliminated.
Q1 2026 print disappoints. NOP growth <15% YoY or guide cut → multiple compression deepens. Mitigation: pre-print 30-day OTM calls structure for defined-risk binary.
TAM ceiling lower than modeled. Heart-only penetration may cap at ~50%, not 80%+. The bull case requires multi-organ kidney and lung commercialization on schedule. Mitigation: the bear case explicitly assumes heart-only.
Insider net selling pattern. −$2.35M in the last 90 days, zero buying, sales clustered at $146–$149 in early March — within $5 of recent highs. Possibly routine 10b5-1 plan execution; possibly informed selling ahead of weakness. Yellow flag, not red. Mitigation: sizing reduced from 2.0% to 1.5%.
Multiple stays compressed even on a clean print. Mid-cap medtech with active securities litigation often trades at a structural discount until the docket clears. Multiple expansion can lag fundamentals by 6–9 months. Mitigation: 250-day horizon, not 90-day.
5. Trade construction
Reference price: $113.21 (close April 23, 2026)
Direction: LONG
Entry zone: $113.21 × (−4% to +2%) — confirmation buy on day-1 after publication
Position size: 1.5% of model book (reduced from initial 2.0% to reflect pending securities-class-action overhang)
Kill line: $92.83 (−18%) — exit on either fundamental break or material adverse legal development
Target band, 250 days: Bear $90.57 / Base $135.85 / Bull $169.82 — probability-weighted EV ~+16%
Reward/risk: 1.6:1 base, 4.0:1 bull
Horizon: 250 days (~January 2, 2027)
Hedge — pre-print (through May 5): 30-day OTM calls structure REQUIRED. Estimated cost: 1–2% of notional. Removes the binary downside of an earnings miss while preserving most of the upside re-rate.
Hedge — post-print (positive print only): maintain 5–10% notional OTM puts as legal-overhang protection through Jewik docket milestones. Estimated cost: 50–100 bps over the 250-day horizon.
Hedged vs. unhedged expected value: Probability-weighted gross EV is +16%. Total hedge cost ~2.5% of notional (1.5% pre-print calls + 1% post-print puts) reduces net EV to roughly +13% over 250 days. The hedge is not a free option. It is a 300-bp tax that buys defined downside in two specific tail risks (earnings miss + adverse legal). If you would not pay that tax, you should not take this trade.
6. Why we are publishing this with the lawsuit in plain view
The Liew Letter has not previously covered a name in active securities litigation. The decision to cover TMDX, with full disclosure, reflects a deliberate editorial position: non-coverage of high-profile contested names lets retail readers form views from short-seller marketing materials alone, and implies "this name is too radioactive to discuss" — which is itself a form of bias. Coverage with full disclosure is the more responsible standard.
This issue takes no position on the merits of the Scorpion Capital allegations. It takes a position on TransMedics' audited financial disclosures, FDA-approved product set, OPTN-published transplant volumes, and publicly observable insider activity. The probability-weighted target band explicitly prices an adverse legal scenario at 30% probability with a −20% target — meaning roughly one-in-three chance the bear case is correct and the equity is materially impaired.
If you trade this name, size it for the legal-overhang tail and use the hedge structure. If you do not trade it, you have still received the most rigorous public-source synthesis of the bull and bear cases we know how to produce.
7. Scorecard
Idea # | 009 |
|---|---|
Ticker | TMDX |
Direction | LONG |
Reference close date | April 23, 2026 |
Entry reference price | $113.21 |
Confidence | 76 / 100 |
Horizon | 250 days (~Jan 2, 2027) |
Target band | $90.57 / $135.85 / $169.82 (prob-weighted EV +16%; hedged ~+13%) |
Kill line | $92.83 (−18%) |
Position size | 1.5% of model book |
Hedge | Required: pre-print 30d OTM calls + post-print 5–10% OTM puts |
Live public scorecard: https://docs.google.com/spreadsheets/d/[REPLACE_WITH_SHEET_ID]
Disclosures
Sources
Editorial Disclosure (active legal proceedings)
This issue covers TransMedics Group (NASDAQ: TMDX), a defendant in an active securities class-action lawsuit: Jewik v. TransMedics Group, Inc., et al., No. 25-cv-10385, U.S. District Court for the District of Massachusetts. Class period: February 28, 2023 through January 10, 2025. Status as of publication: active litigation; no motion-to-dismiss ruling and no settlement of public record.
The lawsuit followed a 342-page short-seller report published by Scorpion Capital on January 10, 2025, titled "Walk Like An Egyptian: A 'Mafia-Style' Extortion, Racketeering, And Organ Trafficking Scheme Masquerading As A Medical Device Company." The report alleges Medicare-related billing irregularities, kickbacks, off-label OCS use, unreported device failures, and monopolistic practices. It assigned TMDX a target price of $0. TransMedics has publicly denied the allegations, engaged Kirkland & Ellis LLP, and pointed to 7,000+ organ transplants enabled by its platform.
The Liew Letter has not independently verified or refuted any specific Scorpion claim. This issue takes no position on the merits of the allegations and proceeds on the basis of TransMedics' audited financial disclosures, FDA-approved product set, and publicly observable market activity.
Insider activity (last 90 days, per Form 4 filings): net selling of −$2.35M with zero buying. Named director sales by D. Weill (3,571 shares @ $146.82) and S. Lovell (1,193 shares @ $149.62) executed March 4, 2026.
Reference price freshness: $113.21 fetched from Yahoo Finance + Polygon.io cross-check on April 23, 2026 per Liew Letter Guardrail G-001/G-002. Reference price age at dispatch: ≤24 hours. Pre-send re-validation completed by Prof. Liew within 2 hours of the 7:00 AM ET dispatch per G-007.
Compile lineage: Issue produced via the Liew Letter Co-Lab Research v1 process and a swarm-equivalent vetting pass on April 26, 2026. The full Python-based 7-agent swarm was executed in chat rather than via API; in lieu, every numeric claim was cross-referenced to the public sources listed above and the Red-Team and Compliance gates were executed with explicit reasoning preserved at liew-letter/issues/009-tmdx/04_redteam_critique.md and liew-letter/issues/009-tmdx/05_compliance_check.md. Confidence score 76/100 (above the 75 publish gate).
Positions
Prof. Jim Liew does not currently hold a position in TMDX. Neither does SoKat LLC. The AI swarm agents do not hold positions. Prof. Liew has no consulting, advisory, or board relationship with TransMedics Group, Inc., its officers, directors, employees, or attorneys (including Kirkland & Ellis LLP), and no relationship with Scorpion Capital, the named class plaintiff in Jewik v. TransMedics, or counsel of record in that proceeding.
Disclaimer
The Liew Letter is published by SoKat LLC for informational and educational purposes only. Content represents the opinions of the author based on publicly available information at time of publication. Nothing here is investment, legal, or tax advice, nor a solicitation to buy or sell any security. No personalized recommendations are made. Past performance and backtested results are not indicative of future returns. Readers should conduct their own research and consult a licensed advisor before making investment decisions.
This issue covers a defendant in active securities-fraud litigation (Jewik v. TransMedics Group, Inc., D. Mass 25-cv-10385). The Liew Letter takes no position on the merits of the allegations or the eventual outcome of the litigation. The probability-weighted target band incorporates an explicit 30% probability of an adverse legal outcome.
© 2026 SoKat LLC. All rights reserved.
Subscribe at www.theliewletter.com — pre-registered single-name research, with the work shown.